INNOVATIVE THINKING
RIGOROUS APPROACHES
REAL WORLD IMPACT

 

IMPAQ International to Provide Analytic, Program Support for Comprehensive End-Stage Renal Disease Care Initiative

Initiative by CMS to Improve Outcomes, Reduce Expenditures for Beneficiaries With ESRD
Washington, DC

|

August 07, 2013

IMPAQ International, LLC, a premier research, evaluation, and technical assistance firm, announced today that it has been awarded a 5-year, $12M, contract by CMS to provide a broad range of analytic and program support activities for a new service delivery and payment initiative specific to Medicare beneficiaries with end-stage renal disease (ESRD). 

The new initiative, called the Comprehensive ESRD Care  Initiative, aims to improve outcomes for Medicare beneficiaries with ESRD and reduce total expenditures by creating financial incentives for dialysis facilities, nephrologists, and other Medicare providers and suppliers to collaboratively and comprehensively address the extensive needs of this complex population. 

“Medicare beneficiaries with ESRD are among the most medically complex populations served by the Medicare program. In 2010, they comprised 1.3% of the Medicare population and accounted for an estimated 7.5% of total Medicare spending,” said Dr. Donald Nichols, IMPAQ’s Health Care Financing Practice Area Lead.

“Beneficiaries with ESRD have extremely high rates of hospital admission and readmission, and clinical management of this population is complicated by significant fragmentation of care,” he added.

Nichols, who will lead the IMPAQ project team, noted that IMPAQ’s scope of work will include developing quality measures, analyzing financial performance, monitoring program adherence, as well as other support activities.

“IMPAQ will work with CMS and our partners to test, in the Initiative, whether financial risk arrangements with guaranteed discounts to the Medicare program will improve key care processes such as chronic disease management,” he added.

IMPAQ will also evaluate the impact of these arrangements on clinical outcomes, such as transplantation rates, mortality rates, and disease complications; whether they improve a patient’s experience of care, quality of life, and functional status; whether they enhance the management of care transitions; whether they reduce utilization of key services such as emergency department visits, hospitalizations, and readmissions; and whether these arrangements reduce Medicare expenditures.